Skip to main content
Content Starts Here GSA Federal Advisory Committee Act (FACA) Database Skip to main content

Committee Detail

Hide Section - GENERAL INFORMATION

GENERAL INFORMATION

Committee NameNational Cancer Advisory BoardAgency NameDepartment of Health and Human Services
Fiscal Year2019Committee Number960
Original Establishment Date11/20/1985Committee StatusChartered
Actual Termination Date Committee URLhttp://deainfo.nci.nih.gov/advisory/ncab/ncab.htm
New Committee This FYNoPresidential Appointments*Yes
Terminated This FYNoMax Number of Members*30
Current Charter Date5/31/2018Designated Fed Officer Position Title*DIRECTOR, DIVISION OF EXTRAMURAL ACTIVITIES, NCI
Date Of Renewal Charter5/31/2020Designated Federal Officer Prefix
Projected Termination Date Designated Federal Officer First Name*PAULETTE
Exempt From Renewal*NoDesignated Federal Officer Middle NameS.
Specific Termination AuthorityDesignated Federal Officer Last Name*GRAY
Establishment Authority*Statutory (Congress Created)Designated Federal Officer SuffixPH.D.
Specific Establishment Authority*42 U.S.C. 284aDesignated Federal Officer Phone*240-276-6340
Effective Date Of Authority*11/20/1985Designated Federal Officer Fax*240-276-7815
Committee Type*ContinuingDesignated Federal Officer Email*grayp@mail.nih.gov
Presidential*No
Committee Function*Other Committee
Hide Section - RECOMMENDATION/JUSTIFICATIONS

RECOMMENDATION/JUSTIFICATIONS

Agency Recommendation*Continue
Legislation to Terminate RequiredNot Applicable
Legislation StatusNot Applicable
How does cmte accomplish its purpose?*The National Cancer Advisory Board (NCAB), composed of both scientific and public members, provides second level peer review, makes recommendations for support of grants, contract proposals, and cooperative agreements, where direct costs per annum exceed $50,000; advises on policy development, program implementation and evaluation; and identifies research needs of the National Cancer Institute (NCI). In FY 2018, the NCAB reviewed 15,120 NCI applications requesting $5,142,273,938 and 7 FDA SBIR applications requesting $1,542,025. During the year, the NCAB was presented reports on various topics related to cancer research in general. Board discussions and reports included a wide variety of topics including the President’s Cancer Panel Report on Promoting Value, Affordability, and Innovation in Cancer Drug Treatment; Cervical Cancer Screening; the Common Terminology for Patient-Reported Outcomes for Adverse Events; Early Career Investigators; Next Steps in Studying the Human Microbiome in Epidemiologic Studies; Next Generation Sequencing (NGS) Coverage Determination; T-Cells as a Drug for the Personalized Immunotherapy of Cancer; and Inter- and Intra-Tumoral Heterogeneity in Pediatric Sarcomas. NCAB members provided insights regarding reports from the NCAB Ad Hoc Subcommittee reports on Global Cancer Research; Population Sciences, Epidemiology, and Disparities; and the BSA Ad Hoc Subcommittee on Human Immunodeficiency Virus (HIV) and Acquired Immune Deficiency Syndrome (AIDS) Malignancy. The Board deliberated on and approved a final report from the Ad Hoc Global Health Working Group and an interim report from the Ad Hoc Data Science Working Group. At the Joint Meeting of the National Advisory Council on Alcohol Abuse and Alcoholism, National Advisory Council on Drug Abuse and NCAB met to hear reports regarding the Adolescent Brain and Cognitive Development (ABCD) Study; a presentation from the U.S. Surgeon General regarding Better Health Through Better Partnerships; and updates from the NIAAA, NIDA, and NCI regarding efforts associated with the Collaborative Research on Addiction at NIH (CRAN) initiative. Lastly, NCAB meeting minutes for the September 2017 meeting, November 2017 Joint NCI Board of Scientific Advisors/NCAB meeting, the NIAAA/NIDA/NCAB May 2018 meeting, the February 2018 meeting and the June 2018 Joint NCI Board of Scientific Advisors/NCAB meeting were approved by the Board members during fiscal year 2018.
How is membership balanced?*The NCAB consists of 18 members appointed by the President. Not more than twelve of the appointed members are selected from among leading representatives of the health and scientific disciplines (including one in public health and one in the behavioral or social sciences) that are relevant to the activities of the NCI. Not more than six of the appointed members are representatives from the general public, including leaders in fields of public policy, law, health policy, economics and management. Not less than five of the appointed members are individuals knowledgeable in environmental carcinogenesis (including carcinogenesis involving occupational and dietary factors).
How frequent & relevant are cmte mtgs?*Meetings are held not less than four times a year. The committee met five times during this reporting period. The Board met jointly with NIAAA/NIDA on May 16, 2018 and jointly with the NCI Board of Scientific Advisors for the November 2017 and June 2018 meeting. The Board also met virtually at the February 2018 and August 2018 meetings. The NCAB provides advice on a continuing basis on the type of scientific research programs that should be supported and on how best to carry out the designated mission and responsibilities of the NCI. In addition, this Board provides ongoing review of the relevance and effectiveness of the existing scientific programs. The Ad hoc Subcommittee on Global Cancer Research and Ad Hoc Subcommittee on Population Science, Epidemiology and Disparities met on November 28, 2017. The Ad Hoc Subcommittee on Population Science, Epidemiology and Disparities and Ad hoc Subcommittee on Global Cancer Research met on June 25, 2018. The Ad Hoc Working Group on Global Health met April 30, 2018. The Ad Hoc Working Group on Data Science met on May 22, July 25, and September 18, 2018. The Ad Hoc Working Group on SBIR/STTR met on May 29, July 24 and September 20-21, 2018. The Ad Hoc Working Group on Strategic Approaches and Opportunities in Population Science, Epidemiology, and Disparities met on July 19, August 22, September 6, and September 20, 2018.
Why advice can't be obtained elsewhere?*The NCAB provides second level of peer review and advises on policy development; program implementation, and evaluation; and identifies research needs and opportunities of the Institute. The quality, scope, and balance of advice from this Board cannot be obtained from NIH staff or from other established sources as membership of the Board is constituted to meet specific requirements of the mandated mission of the Board and of the NCI.
Why close or partially close meetings?The meetings of the NCAB were closed to the public for the review of grant applications. Sections 552b(c)(4) and 552b(c)(6) of the Government in the Sunshine Act permit the closing of meetings where discussion of applications could reveal confidential trade secrets or commercial property such as patentable material and personal information, disclosure of which would constitute a clearly unwarranted invasion of personal privacy.
Recommendation RemarksCommittee Function: Other - National Scientific and Advisory.

Costs: The increase in operating costs for FY18 is due to an increase in the number of NCAB working groups and the number of meetings held.

Ex Officio Members: The terms of service for Michael Babich, Vincent Cogliano, Aubrey Miller, Richard Pazdur, and Craig Shriver have been extended. As such, their term of service dates are different than what was reported on the FY17 ACR.

Members: The terms of service for David Christiani, Judy Garber, Elizabeth Jaffee, Beth Karlan, Mack Roach, and Charles Sawyers have changed due to administrative extensions. As such, their term of service dates are different than what was reported on the FY17 ACR.

The DFO and Committee Decision Maker positions are held by the same individual because of the assignment of responsibilities within the Institute.
Hide Section - PERFORMANCE MEASURES

PERFORMANCE MEASURES

Outcome Improvement To Health Or Safety*YesAction Reorganize Priorities*Yes
Outcome Trust In GovernmentNoAction Reallocate ResourcesYes
Outcome Major Policy ChangesYesAction Issued New RegulationsNo
Outcome Advance In Scientific ResearchYesAction Proposed LegislationNo
Outcome Effective Grant MakingYesAction Approved Grants Or Other PaymentsYes
Outcome Improved Service DeliveryNoAction OtherYes
Outcome Increased Customer SatisfactionNoAction CommentAn action of approved or recommended for grants receiving review by this Council does not infer that the grant will be or has been funded. Research grant applications submitted to NIH must go through a two-step review process that includes the initial peer review for scientific and technical merit and a second step of review and approval by the National Advisory Council that includes program relevance. In addition, prior to an award or funding being made, NIH staff must conduct an administrative review for a number of other considerations. These include alignment with NIH's funding principles, review of the project budget, assessment of the applicant's management systems, determination of applicant eligibility, and compliance with public policy requirements. After all these steps, have been completed, NIH officials make funding decisions on individual grant applications. NCI used its resources to support the best science and ensure continued advances with a focus on the Cancer Moonshot recommendations and associated implementation plans. There were also discussions on early stage investigators and NCI’s proposed implementation plan for the NIH Next-General Researchers Initiative which included establishing the NCI Early Cancer Investigator (ECI), awarding successful ECI applications for 5 plus 2 years, providing mentoring for ECIs, and continuing to expend efforts to increase diversity of the NCI-funded workforce. The Board provided insights on NCI’s key focus areas – reaffirming commitment to basic science to drive novel approaches and technologies; increasing data aggregation and interpretation to speed work across the cancer enterprise; supporting the cancer research enterprise by focusing on the workforce of cancer investigators; and realizing the power of clinical trials through innovative design, administration, and analyses. NCAB members gave thoughtful advice on several scientific advances presented regarding cervical cancer screening, the human microbiome in epidemiologic studies, the use of T-Cells as a drug for personalized immunotherapy of cancer, and inter- and intra-tumoral heterogeneity in pediatric sarcomas. Additionally, there were discussions regarding the Interim Ad Hoc Data Science Working Group Report and the Final Ad Hoc Global Health Working Group Report which were presented, deliberated, and approved at the August 2018 NCAB Meeting.
Outcome Implement Laws/Reg RequirementsYesGrants Review*Yes
Outcome OtherYesNumber Of Grants Reviewed15,127
Outcome CommentThe NCAB continues to be instrumental in monitoring the development and execution of the activities of the National Cancer Program, which conducts and supports research, training, health information dissemination, and other programs with respect to the cause, diagnosis, prevention, and treatment of cancer, rehabilitation from cancer, and the continuing care of cancer patients and the families of cancer patients. In 2018, NCI used its resources to support the best science and ensure continued advances with a focus on the Cancer Moonshot recommendations and associated implementation plans. There were also discussions on early stage investigators and NCI’s proposed implementation plan for the NIH Next-General Researchers Initiative which included establishing the NCI Early Cancer Investigator (ECI), awarding successful ECI applications for 5 plus 2 years, providing mentoring for ECIs, and continuing to expend efforts to increase diversity of the NCI-funded workforce. The Board provided insights on NCI’s key focus areas – reaffirming commitment to basic science to drive novel approaches and technologies; increasing data aggregation and interpretation to speed work across the cancer enterprise; supporting the cancer research enterprise by focusing on the workforce of cancer investigators; and realizing the power of clinical trials through innovative design, administration, and analyses. NCAB members gave thoughtful advice on several scientific advances presented regarding cervical cancer screening, the human microbiome in epidemiologic studies, the use of T-Cells as a drug for personalized immunotherapy of cancer, and inter- and intra-tumoral heterogeneity in pediatric sarcomas. Additionally, there were discussions regarding the Interim Ad Hoc Data Science Working Group Report and the Final Ad Hoc Global Health Working Group Report which were presented, deliberated, and approved at the August 2018 NCAB Meeting.Number Of Grants Recommended15,127
Cost Savings*Unable to DetermineDollar Value Of Grants Recommended$5,143,815,963.00
Cost Savings CommentNIH supported basic and clinical research accomplishments often take many years to unfold into new diagnostic tests and new ways to treat and prevent diseases.Grants Review CommentThe number of grants reviewed/recommended and dollar value includes NCI grants and FDA SBIR grants.
Number Of Recommendations*183Access Contact Designated Fed. Officer*Yes
Number Of Recommendations CommentComments: FY 2018 recommendations include the following: 1. A motion to confirm the 14–15 August 2018 and 3–5 September 2019 meeting dates of the NCAB was approved unanimously. 2. A motion to accept the minutes of the 12 September 2017 NCAB meeting was approved unanimously. 3. A motion to accept the report of the 28 November 2017 NCAB Ad Hoc Global Cancer Research Subcommittee meeting was approved unanimously. 4. A motion to accept the report of the 28 November 2017 NCAB Ad Hoc Population Sciences, Epidemiology, and Disparities Subcommittee meeting was approved unanimously. 5. Motions (4 total) to establish NCAB Ad Hoc Working Groups on Global Health; Informatics; Strategic Approaches and Opportunities in Population Science, Epidemiology, and Disparities; and Small Business Innovation Research (SBIR)/Small Business Technology Transfer Research (STTR) were approved unanimously. 6. A motion to accept the minutes of the 29 November 2017 Joint Boards meeting was approved unanimously. 7. A motion to approve the NCI Annual Delegations of Authority was approved unanimously. 8. A motion to accept the minutes of the February 13, 2018 NCAB meeting was approved unanimously. 9. A motion to accept the report of the June 25, 2018 NCAB Ad Hoc Global Cancer Research Subcommittee meeting was approved unanimously. 10. A motion to accept the report of the June 25, 2018 NCAB Ad Hoc Population Science, Epidemiology, and Disparities Subcommittee meeting was approved unanimously. 11. A motion to accept the minutes of the June 26–27, 2018 NCAB and Board of Scientific Advisors Joint Meeting was approved unanimously. 12. A motion to accept the interim report of the NCAB ad hoc Data Science Working Group was approved unanimously. 13. A motion to accept the final report of the NCAB ad hoc Global Health Working Group was approved unanimously.Access Agency WebsiteYes
% of Recs Fully Implemented*0.00%Access Committee WebsiteYes
% of Recs Fully Implemented CommentInformation on the research funded by NIH is available through the RePORT (Research Portfolio Online Reporting Tool) website. RePORT provides access to reports, data, and analyses of NIH research activities that advance the mission of the NIH, including information on NIH expenditures, strategic plans, reports on NIH funding, and reports on the organization and people involved in NIH research and research training. The RePORT website is located at http://report.nih.gov.Access GSA FACA WebsiteYes
% of Recs Partially Implemented*0.00%Access PublicationsYes
% of Recs Partially Implemented CommentInformation on the research funded by NIH is available through the RePORT (Research Portfolio Online Reporting Tool) website. RePORT provides access to reports, data, and analyses of NIH research activities that advance the mission of the NIH, including information on NIH expenditures, strategic plans, reports on NIH funding, and reports on the organization and people involved in NIH research and research training. The RePORT website is located at http://report.nih.gov.Access OtherYes
Agency Feedback*YesAccess CommentInformation on the NCAB can be found at the NCI Division of Extramural Activities: Advisory Boards, Committees and Review Groups website at https://deainfo.nci.nih.gov/advisory/ncab/ncab.htm. Each NCI committee’s charter, minutes, agenda, roster, future meeting dates, meeting PowerPoint Presentations and reports is located here. Additionally, the public may view the NCAB meetings (both live and on demand) via the NIH Videocast at the following website: http://videocast.nih.gov/.
Agency Feedback CommentNCI Director and Deputy Directors report at each Board Meeting; the President's Cancer Panel Report; NCI Annual Reports; Biennial reports; and a list of Action Items for each meeting are reviewed and assigned to individual NCI staff with specific time frames with deadlines.Narrative Description*The goal of NIH research is to acquire new knowledge to help prevent, detect, diagnose, and treat disease and disability, from the rarest genetic disorder to the common cold. The National Cancer Institute coordinates the National Cancer Program, which conducts and supports research, training, health information dissemination, and other programs with respect to the cause, diagnosis, prevention, and treatment of cancer, rehabilitation from cancer, and the continuing care of cancer patients and the families of cancer patients. NCI works to fufill that mission with the support of the National Cancer Advisory Board (NCAB), which is composed of both scientific and public members, and provides second level peer review, makes recommendations for support of grants, contract proposals, and cooperative agreements, where direct costs per annum exceed $50,000; advises on policy development, program implementation and evaluation; and identifies research needs of the National Cancer Institute (NCI). During the year, the NCAB was presented reports on various topics related to cancer research in general, and the operational aspects of the Institute's intramural and extramural programs. The NCAB provides advice on a continuing basis on the type of scientific research programs that should be supported and on how best to carry out the designated mission and responsibilities of the NCI. In addition, this Board provides ongoing review of the relevance and effectiveness of the existing research programs.
Hide Section - COSTS

COSTS

Payments to Non-Federal Members* Est Payments to Non-Fed Members Next FY* 
Payments to Federal Members* Est. Payments to Fed Members Next FY* 
Payments to Federal Staff* Estimated Payments to Federal Staff* 
Payments to Consultants* Est. Payments to Consultants Next FY* 
Travel Reimb. For Non-Federal Members* Est Travel Reimb Non-Fed Members nextFY* 
Travel Reimb. For Federal Members* Est Travel Reimb For Fed Members* 
Travel Reimb. For Federal Staff* Est. Travel Reimb to Fed Staff Next FY* 
Travel Reimb. For Consultants* Est Travel Reimb to Consultants Next FY* 
Other Costs Est. Other Costs Next FY* 
Total Costs$0.00Est. Total Next FY*$0.00
Federal Staff Support (FTE)* Est. Fed Staff Support Next FY* 
Hide Section - Custom Links

Custom Links

     Committee Level Reports               
Hide Section - MEMBERS,MEETINGS AND ADVISORY REPORTS

MEMBERS,MEETINGS AND ADVISORY REPORTS

To View all the members, meetings and advisory reports for this committee please click here
Hide Section - CHARTERS AND RELATED DOCS

CHARTERS AND RELATED DOCS

No Documents Found
Hide Section - DATA FROM PREVIOUS YEARS

DATA FROM PREVIOUS YEARS

Committee

Data from Previous Years

 
ActionCommittee System IDCommittee NameFiscal Year
 COM-034864National Cancer Advisory Board2018
 COM-001697National Cancer Advisory Board2017
 COM-002625National Cancer Advisory Board2016
 COM-004095National Cancer Advisory Board2015
 COM-004406National Cancer Advisory Board2014
 COM-005879National Cancer Advisory Board2013
 COM-006663National Cancer Advisory Board2012
 COM-007989National Cancer Advisory Board2011
 COM-008841National Cancer Advisory Board2010
 COM-010335National Cancer Advisory Board2009
 COM-010812National Cancer Advisory Board2008
 COM-012087National Cancer Advisory Board2007
 COM-012898National Cancer Advisory Board2006
 COM-013966National Cancer Advisory Board2005
 COM-014620National Cancer Advisory Board2004
 COM-015893National Cancer Advisory Board2003
 COM-016493National Cancer Advisory Board2002
 COM-018011National Cancer Advisory Board2001
 COM-018728National Cancer Advisory Board2000
 COM-019867National Cancer Advisory Board1999
 COM-020396National Cancer Advisory Board1998
 COM-021687National Cancer Advisory Board1997